<SEC-DOCUMENT>0000950170-25-093467.txt : 20250702
<SEC-HEADER>0000950170-25-093467.hdr.sgml : 20250702
<ACCEPTANCE-DATETIME>20250702210006
ACCESSION NUMBER:		0000950170-25-093467
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20250701
FILED AS OF DATE:		20250702
DATE AS OF CHANGE:		20250702

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Mulroy Michael H.
		CENTRAL INDEX KEY:			0001509725
		ORGANIZATION NAME:           	

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-12830
		FILM NUMBER:		251103539

	MAIL ADDRESS:	
		STREET 1:		1300 N. KELLOGG DRIVE, SUITE D
		CITY:			ANAHEIM
		STATE:			CA
		ZIP:			92807

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Lineage Cell Therapeutics, Inc.
		CENTRAL INDEX KEY:			0000876343
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				943127919
		STATE OF INCORPORATION:			CA
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		2173 SALK AVENUE
		STREET 2:		SUITE 200
		CITY:			CARLSBAD
		STATE:			CA
		ZIP:			92008
		BUSINESS PHONE:		5105213390

	MAIL ADDRESS:	
		STREET 1:		2173 SALK AVENUE
		STREET 2:		SUITE 200
		CITY:			CARLSBAD
		STATE:			CA
		ZIP:			92008

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BIOTIME INC
		DATE OF NAME CHANGE:	19930328
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>ownership.xml
<DESCRIPTION>4
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0508</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2025-07-01</periodOfReport>

    <issuer>
        <issuerCik>0000876343</issuerCik>
        <issuerName>Lineage Cell Therapeutics, Inc.</issuerName>
        <issuerTradingSymbol>LCTX</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001509725</rptOwnerCik>
            <rptOwnerName>Mulroy Michael H.</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O LINEAGE CELL THERAPEUTICS</rptOwnerStreet1>
            <rptOwnerStreet2>2173 SALK AVENUE, SUITE 200</rptOwnerStreet2>
            <rptOwnerCity>CARLSBAD</rptOwnerCity>
            <rptOwnerState>CA</rptOwnerState>
            <rptOwnerZipCode>92008</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>true</isDirector>
            <isOfficer>false</isOfficer>
            <isTenPercentOwner>false</isTenPercentOwner>
            <isOther>false</isOther>
        </reportingOwnerRelationship>
    </reportingOwner>

    <aff10b5One>false</aff10b5One>

    <derivativeTable>
        <derivativeTransaction>
            <securityTitle>
                <value>Stock Option (Right to Buy)</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>0.8977</value>
            </conversionOrExercisePrice>
            <transactionDate>
                <value>2025-07-01</value>
            </transactionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>A</transactionCode>
                <equitySwapInvolved>false</equitySwapInvolved>
            </transactionCoding>
            <transactionAmounts>
                <transactionShares>
                    <value>75000</value>
                </transactionShares>
                <transactionPricePerShare>
                    <value>0.00</value>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>A</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <exerciseDate>
                <footnoteId id="F1"/>
            </exerciseDate>
            <expirationDate>
                <value>2035-07-01</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Shares</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>75000</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>75000</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeTransaction>
    </derivativeTable>

    <footnotes>
        <footnote id="F1">Will vest and become exercisable on the earlier of July 1, 2026 and the date of the issuer's next annual meeting of shareholders, subject in any case to the reporting person's continuous service with the issuer.</footnote>
    </footnotes>

    <ownerSignature>
        <signatureName>/s/ Alexandra Hernandez, as Attorney-in-Fact</signatureName>
        <signatureDate>2025-07-03</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
